Wide-scale study will examine efficacy of three Alzheimer's drugs
Test subjects will include 160 adults 'doomed to come down with Alzheimer's
Three drugs intended to stave off the effects of Alzheimer's - the heinous disease that robs the elderly of their memory and the thought process - will be tested in a large scale study on three continents. The study will examine 160 people in Great Britain, the United States and Australia who are genetically disposed to get the condition. The study will take place over five years, at which time the subjects are expected to develop Alzheimer's.
Researchers will follow the subjects with scans and memory tests in the first two years of the study, looking for signs that the drugs are working.
Another study starting next year involves an extended family in Colombia that shares the mutation that causes the disease. A third study will involve people in the U.S., aged 70 and older who seem perfectly healthy and who do not have any known Alzheimer's mutations but who have brain scans that show the disease is manifesting itself.
Studies involving people who already have Alzheimer's have failed. Scientists have begun to call for studies in those who do not yet have the disease, saying that the time to intervene is before the brain is irreversibly damaged. The initial study, where people who are destined to get Alzheimer's unless a drug can stop it is a way to test that idea.
"It's an exciting opportunity," Dr. Ronald Petersen, director of the Alzheimer's disease Research Center at the Mayo Clinic says. Petersen is not involved with the study.
Vice President of Medical and Scientific relations at the Alzheimer's Association Maria C. Carrillo says that the results will come quickly. As researchers simultaneously compare the three approaches to stopping the disease over the five years, they should know which drug -- if any -- is going to work. The association contributed $4.2 million to the study, more than twice as much as it has ever spent on a grant, Carrillo says.
Investigators have found ways of spotting and tracking the progression of the disease before any clinical symptoms appear over the past several years, using brain scans and spinal taps and sensitive tests of memory. Many think they are on the brink of a new era in which drugs can be assessed without waiting for effects on profound symptoms.
Deemed DIAN TU, which stands for Dominantly Inherited Alzheimer's Network Trials Unit, the study is designed to get the most information possible in as short a time as possible. Three-quarters of the subjects will get one of three drugs aimed at beta amyloid, a protein that forms the hard plaques on the brain that are the hallmark of Alzheimer's.
The three drugs were chosen from among 15 that drug companies offered. A committee assessed them, looking for drugs with the best evidence of effectiveness and the least likelihood of dangerous side effects.
Researchers will follow the subjects with scans and memory tests in the first two years of the study, looking for signs that the drugs are working. If one or more seems clearly effective, they will switch all the subjects to it and continue the study, looking for clinical benefits.
The drugs to be tested are gantenerumab, made by Roche, which binds to clumps of amyloid and allows it to be removed from the brain, and two drugs by Lilly. One, known as LY2886721, blocks an enzyme, beta-secretase, used to make amyloid. The other, solanezumab, attaches itself to amyloid that is floating free in the brain before it clumps into plaques, facilitating its removal.
© 2012, Distributed by NEWS CONSORTIUM.
Pope Francis Prayer Intentions for December 2013
General Intention: Victimized Children. That children who are victims of abandonment or violence may find the love and protection they need.
Missionary Intention: Prepare the Savior's Coming. That Christians, enlightened by the Word incarnate, may prepare humanity for the Savior's coming.
Rate This Article
Leave a Comment
More Health News
- Obamacare crashing in model states like California as 70 percent of doctors opt out
- New hepatitis-C drug approved by FDA
- Donors from around the world say that an AIDS-free generation may be within sight
- Washington signing up more people for Medicaid than private plans
- Man documents ravages of diabetes to his feet as they decay within 10 DAYS
- Dementia epidemic only growing worse: 135 million sufferers could arrive by 2050
- Men are from Mars, Women from Venus? Their brains are certainly wired differently
- Drinking water from plastic cups, bottles may be causing migraine headaches
- Apocalypse imminent as bacteria evolve beyond antibiotics
- Fr. Paul Schenck: Finding Living Faith on Catechetical Sunday
- The Movie Yellow: Incest as 'Normal' and Cassavates's Slides Into the World of Woes
- The Chicago School Teachers Strike Reveals the Need For School Choice
- The Sexual Barbarians and the Dissolution of Culture
- The Happy Priest Challenges Us to Ask: Who is Jesus to Me?
- Michael Coren on Canadian Public Schools: Teachers, leave those kids alone
- We Cannot Ignore Our Consciences: Cardinal Dolan On Religious Liberty
- In the Face of Danger, Successor of Peter Travels to Lebanon as a Messenger of Peace
- Reflections on the Dignity and Vocation of Women: Who or What?